Jens-Ulrich Buelow

Title: **Jens-Ulrich Buelow: Innovator in Humanized Antibodies**

Introduction

Jens-Ulrich Buelow, based in Karlsruhe, Germany, is an accomplished inventor known for his significant contribution to the field of biotechnology. With a focus on humanized antibodies, his work aims to enhance therapeutic treatments for human subjects.

Latest Patents

Buelow holds a patent for the "Production of humanized antibodies in transgenic animals." This groundbreaking invention entails the use of genetically engineered non-human animals that contain one or more humanized immunoglobulin loci. These animals are capable of undergoing gene rearrangement and gene conversion, leading to the production of diversified humanized immunoglobulins. The innovation also encompasses novel sequences, recombination vectors, and transgenic vectors that facilitate the creation of these transgenic animals. The resulting humanized antibodies exhibit minimal immunogenicity to humans, making them suitable for therapeutic applications.

Career Highlights

Currently, Jens-Ulrich Buelow is associated with Therapeutic Human Polyclonals Inc., where he continues to push the boundaries of science and develop innovative solutions for treating various human conditions. His dedicated research has established him as a notable figure in the realm of antibody production.

Collaborations

Throughout his career, Buelow has collaborated with esteemed professionals, including Roland Buelow and Josef Platzer. These collaborations have enriched his research and contributed to the advancement of technologies in the field of biotechnology.

Conclusion

Jens-Ulrich Buelow is a visionary inventor whose work on humanized antibodies represents a significant advancement in therapeutic treatments. His patent reflects a commitment to innovation and a pursuit of excellence in the field of biotechnology, ultimately aiming to improve human health and wellbeing.